Episode
Scott Brunner (Alliance for Pharmacy Compounding CEO) - Compounders vs. Big Pharma and GLP-1s
- Podcast
- Hims House
- Published
- Sep 9, 2025
- Duration seconds
- 3214
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/scott-brunner-alliance-for-pharmacy-compounding-ceo-compounders-vs-big-pharma-and-glp-1s/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hims-house-7026583/scott-brunner-alliance-for-pharmacy-compounding-ceo-compounders-vs-big-pharma-and-glp-1s.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In Episode 45 of Hims House, hosts Jonathan Stern and Patrick Lester (aka Bayside) welcome Scott Brunner, CEO of the Alliance for Pharmacy Compounding, for a conversation on the future of compounding. They cover the surge in GLP-1 demand, lawsuits involving Eli Lilly and Novo Nordisk, FDA policies, and the regulatory pressures shaping 503A and 503B pharmacies. Brunner also unpacks the challenges around the demonstrably difficult to compound list, compounded hormone therapy, and peptides, while sharing insights into congressional actions and the MAHA movement’s role in protecting patient access to compounded medications. 00:00 - Introduction 01:02 - The Role of the Alliance for Pharmacy Compounding 01:51 - 503Bs Ramping Production? Rumors vs Realities 07:55 - Lawsuits Involving Eli Lilly and Novo Nordisk 11:58 - Patents 15:51 - Policy Negotiations and the MFN Debate 25:06 - Lawmaker Letter to FDA 28:04 - What’s in the APC Blueprint 28:51 - The 5% Rule and MOU Requirements 33:42 - The Demonstrably Difficult to Compound List 41:00 - Compounded Hormone Therapy 43:21 - Peptides Get full access to Hims House at himshouse.substack.com/subscribe